| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium Infections, Nontuberculous | 29 | 2024 | 339 | 6.620 |
Why?
|
| Mycobacterium tuberculosis | 22 | 2024 | 318 | 5.490 |
Why?
|
| Tuberculosis | 17 | 2024 | 283 | 5.320 |
Why?
|
| Nontuberculous Mycobacteria | 21 | 2026 | 189 | 4.200 |
Why?
|
| Lung Diseases | 18 | 2024 | 780 | 3.510 |
Why?
|
| Tuberculosis, Multidrug-Resistant | 14 | 2025 | 47 | 3.390 |
Why?
|
| alpha 1-Antitrypsin | 7 | 2024 | 104 | 3.340 |
Why?
|
| Tuberculosis, Pulmonary | 15 | 2020 | 127 | 2.890 |
Why?
|
| alpha 1-Antitrypsin Deficiency | 7 | 2024 | 61 | 2.860 |
Why?
|
| Antitubercular Agents | 15 | 2025 | 208 | 2.230 |
Why?
|
| Interleukins | 9 | 2019 | 248 | 2.130 |
Why?
|
| Mycobacterium avium Complex | 8 | 2023 | 87 | 2.040 |
Why?
|
| Macrophages | 20 | 2024 | 1507 | 2.010 |
Why?
|
| Macrophages, Alveolar | 9 | 2020 | 373 | 1.920 |
Why?
|
| Mycobacterium avium-intracellulare Infection | 7 | 2023 | 63 | 1.810 |
Why?
|
| Respiratory Tract Infections | 7 | 2019 | 396 | 1.590 |
Why?
|
| Granuloma | 5 | 2024 | 97 | 1.530 |
Why?
|
| Sjogren's Syndrome | 2 | 2024 | 37 | 1.450 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2024 | 129 | 1.420 |
Why?
|
| Smoking | 8 | 2020 | 1472 | 1.160 |
Why?
|
| Humans | 153 | 2025 | 145475 | 1.130 |
Why?
|
| Glucocorticoids | 3 | 2021 | 531 | 1.120 |
Why?
|
| Disease Susceptibility | 6 | 2018 | 344 | 1.080 |
Why?
|
| Interferon-gamma | 12 | 2018 | 784 | 1.070 |
Why?
|
| Lung | 18 | 2023 | 4106 | 1.060 |
Why?
|
| Bronchiectasis | 4 | 2021 | 115 | 0.990 |
Why?
|
| NF-kappa B | 9 | 2022 | 666 | 0.980 |
Why?
|
| Mycobacterium | 6 | 2026 | 101 | 0.970 |
Why?
|
| Pulmonary Emphysema | 2 | 2024 | 277 | 0.900 |
Why?
|
| Interleukin-8 | 6 | 2022 | 269 | 0.900 |
Why?
|
| Epithelial Cells | 6 | 2020 | 1131 | 0.850 |
Why?
|
| Serpins | 1 | 2024 | 28 | 0.810 |
Why?
|
| Antimicrobial Cationic Peptides | 3 | 2020 | 81 | 0.810 |
Why?
|
| Macrophage Activation | 2 | 2021 | 181 | 0.750 |
Why?
|
| Phospholipids | 4 | 2020 | 214 | 0.750 |
Why?
|
| Solitary Pulmonary Nodule | 2 | 2021 | 25 | 0.730 |
Why?
|
| Edema | 2 | 2017 | 125 | 0.730 |
Why?
|
| Nicotine | 3 | 2023 | 331 | 0.730 |
Why?
|
| Latent Tuberculosis | 2 | 2015 | 70 | 0.710 |
Why?
|
| Cigarette Smoking | 1 | 2023 | 102 | 0.710 |
Why?
|
| Tomography, X-Ray Computed | 10 | 2021 | 2769 | 0.710 |
Why?
|
| Apoptosis | 7 | 2020 | 2440 | 0.700 |
Why?
|
| Enoxaparin | 1 | 2022 | 68 | 0.680 |
Why?
|
| Thinness | 2 | 2013 | 100 | 0.670 |
Why?
|
| Respiratory Mucosa | 3 | 2020 | 322 | 0.670 |
Why?
|
| Angioedema | 1 | 2021 | 16 | 0.660 |
Why?
|
| Nitric Oxide | 6 | 2017 | 892 | 0.650 |
Why?
|
| Critical Care | 2 | 2019 | 702 | 0.650 |
Why?
|
| Extensively Drug-Resistant Tuberculosis | 3 | 2009 | 6 | 0.650 |
Why?
|
| Angioedemas, Hereditary | 1 | 2020 | 4 | 0.640 |
Why?
|
| Mycobacterium Infections | 5 | 2023 | 55 | 0.640 |
Why?
|
| Lung Neoplasms | 6 | 2021 | 2664 | 0.610 |
Why?
|
| Anti-Bacterial Agents | 9 | 2024 | 1923 | 0.610 |
Why?
|
| Immunoassay | 1 | 2020 | 109 | 0.600 |
Why?
|
| Funnel Chest | 3 | 2017 | 29 | 0.600 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 468 | 0.600 |
Why?
|
| Immune Evasion | 1 | 2020 | 61 | 0.600 |
Why?
|
| Membrane Lipids | 1 | 2020 | 82 | 0.600 |
Why?
|
| Lipopolysaccharides | 5 | 2022 | 858 | 0.590 |
Why?
|
| Lung Diseases, Fungal | 1 | 2018 | 12 | 0.560 |
Why?
|
| Smoke | 3 | 2020 | 148 | 0.560 |
Why?
|
| Parasitic Diseases | 1 | 2018 | 8 | 0.560 |
Why?
|
| Microbial Viability | 3 | 2020 | 83 | 0.550 |
Why?
|
| Oximetry | 2 | 2013 | 125 | 0.540 |
Why?
|
| Disease Models, Animal | 5 | 2023 | 4560 | 0.540 |
Why?
|
| Virulence Factors | 2 | 2023 | 174 | 0.540 |
Why?
|
| Pneumonia, Mycoplasma | 3 | 2011 | 55 | 0.530 |
Why?
|
| Fluoroquinolones | 3 | 2018 | 44 | 0.520 |
Why?
|
| Cerebral Hemorrhage | 2 | 2016 | 125 | 0.510 |
Why?
|
| Collateral Circulation | 1 | 2017 | 20 | 0.510 |
Why?
|
| T-Lymphocytes, Regulatory | 5 | 2023 | 409 | 0.500 |
Why?
|
| Scoliosis | 3 | 2017 | 221 | 0.500 |
Why?
|
| Lymphadenopathy | 1 | 2016 | 8 | 0.480 |
Why?
|
| Bacterial Infections | 1 | 2018 | 246 | 0.480 |
Why?
|
| Ciprofloxacin | 1 | 2016 | 31 | 0.480 |
Why?
|
| Multiple Pulmonary Nodules | 1 | 2016 | 23 | 0.470 |
Why?
|
| Vascular Malformations | 1 | 2017 | 52 | 0.470 |
Why?
|
| Vena Cava, Inferior | 1 | 2017 | 83 | 0.470 |
Why?
|
| Hemangioma, Capillary | 2 | 2006 | 14 | 0.470 |
Why?
|
| Thorax | 1 | 2016 | 51 | 0.470 |
Why?
|
| Mycoses | 1 | 2017 | 88 | 0.470 |
Why?
|
| Biofilms | 7 | 2026 | 292 | 0.470 |
Why?
|
| Francisella tularensis | 1 | 2016 | 33 | 0.470 |
Why?
|
| Tularemia | 1 | 2016 | 30 | 0.470 |
Why?
|
| Animals | 34 | 2024 | 38030 | 0.460 |
Why?
|
| Acute Pain | 1 | 2017 | 58 | 0.460 |
Why?
|
| Curcumin | 1 | 2016 | 28 | 0.460 |
Why?
|
| Autophagy | 4 | 2021 | 291 | 0.450 |
Why?
|
| Low Back Pain | 1 | 2017 | 107 | 0.450 |
Why?
|
| Serine Proteinase Inhibitors | 3 | 2024 | 48 | 0.450 |
Why?
|
| Models, Biological | 2 | 2020 | 1764 | 0.430 |
Why?
|
| Cyclonic Storms | 2 | 2015 | 40 | 0.430 |
Why?
|
| Venous Thrombosis | 1 | 2017 | 196 | 0.420 |
Why?
|
| Virus Diseases | 1 | 2017 | 216 | 0.420 |
Why?
|
| Mycobacterium abscessus | 3 | 2021 | 110 | 0.400 |
Why?
|
| Somatostatin | 1 | 2013 | 53 | 0.400 |
Why?
|
| Octreotide | 1 | 2013 | 23 | 0.400 |
Why?
|
| Mycobacterium avium | 5 | 2023 | 21 | 0.400 |
Why?
|
| Disasters | 1 | 2015 | 100 | 0.400 |
Why?
|
| Biomimetic Materials | 1 | 2014 | 78 | 0.400 |
Why?
|
| Mice | 21 | 2023 | 18329 | 0.390 |
Why?
|
| Adaptive Immunity | 3 | 2024 | 167 | 0.390 |
Why?
|
| Cell Line | 9 | 2017 | 2823 | 0.390 |
Why?
|
| Interleukin-4 | 3 | 2009 | 207 | 0.390 |
Why?
|
| Cytokines | 6 | 2024 | 2067 | 0.390 |
Why?
|
| Amikacin | 2 | 2018 | 29 | 0.380 |
Why?
|
| Chemokine CXCL10 | 2 | 2010 | 39 | 0.380 |
Why?
|
| Environmental Exposure | 2 | 2015 | 578 | 0.370 |
Why?
|
| THP-1 Cells | 2 | 2024 | 19 | 0.370 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2015 | 1217 | 0.370 |
Why?
|
| Risk Factors | 12 | 2021 | 10885 | 0.360 |
Why?
|
| Transforming Growth Factor beta | 2 | 2013 | 474 | 0.360 |
Why?
|
| Interleukin-18 | 4 | 2011 | 234 | 0.360 |
Why?
|
| Diagnosis, Differential | 6 | 2021 | 1508 | 0.360 |
Why?
|
| Monocytes | 3 | 2011 | 539 | 0.360 |
Why?
|
| Heparin | 2 | 2024 | 247 | 0.360 |
Why?
|
| Nitric Oxide Synthase | 2 | 2003 | 234 | 0.350 |
Why?
|
| Mycoplasma pneumoniae | 2 | 2011 | 53 | 0.350 |
Why?
|
| Brain Neoplasms | 2 | 2025 | 1329 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2017 | 2378 | 0.330 |
Why?
|
| Cell Membrane | 2 | 2020 | 707 | 0.330 |
Why?
|
| Chemokine CXCL9 | 1 | 2010 | 38 | 0.330 |
Why?
|
| Male | 45 | 2025 | 72843 | 0.320 |
Why?
|
| Serine Endopeptidases | 2 | 2022 | 128 | 0.320 |
Why?
|
| Virulence | 5 | 2023 | 278 | 0.320 |
Why?
|
| Soil Microbiology | 3 | 2026 | 115 | 0.320 |
Why?
|
| Respiratory System | 1 | 2011 | 150 | 0.320 |
Why?
|
| Middle Aged | 30 | 2025 | 36215 | 0.300 |
Why?
|
| Rifampin | 3 | 2025 | 79 | 0.300 |
Why?
|
| Hawaii | 7 | 2026 | 37 | 0.300 |
Why?
|
| Streptomycin | 1 | 2009 | 18 | 0.290 |
Why?
|
| Bronchi | 2 | 2008 | 263 | 0.290 |
Why?
|
| Gene Expression Regulation | 4 | 2024 | 2597 | 0.290 |
Why?
|
| Nitric Oxide Synthase Type II | 5 | 2017 | 162 | 0.280 |
Why?
|
| Female | 45 | 2025 | 78845 | 0.280 |
Why?
|
| Solitary Fibrous Tumor, Pleural | 1 | 2008 | 3 | 0.270 |
Why?
|
| Osteoarthropathy, Secondary Hypertrophic | 1 | 2008 | 3 | 0.270 |
Why?
|
| Up-Regulation | 3 | 2011 | 847 | 0.270 |
Why?
|
| Cells, Cultured | 10 | 2019 | 4148 | 0.270 |
Why?
|
| Wound Healing | 1 | 2010 | 355 | 0.270 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2022 | 477 | 0.270 |
Why?
|
| Treatment Outcome | 12 | 2025 | 11772 | 0.270 |
Why?
|
| Sodium Chloride | 2 | 2006 | 138 | 0.270 |
Why?
|
| Gene Expression | 4 | 2018 | 1476 | 0.260 |
Why?
|
| Prevalence | 8 | 2022 | 2865 | 0.260 |
Why?
|
| Meningitis, Bacterial | 1 | 2008 | 46 | 0.260 |
Why?
|
| Otitis Media | 1 | 2010 | 182 | 0.260 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 441 | 0.260 |
Why?
|
| Cell Cycle | 1 | 2010 | 598 | 0.260 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2010 | 431 | 0.260 |
Why?
|
| Dendritic Cells | 3 | 2021 | 499 | 0.250 |
Why?
|
| Comorbidity | 6 | 2021 | 1661 | 0.250 |
Why?
|
| Public Health | 1 | 2012 | 572 | 0.250 |
Why?
|
| Radiography, Thoracic | 1 | 2008 | 172 | 0.250 |
Why?
|
| Wounds and Injuries | 2 | 2017 | 961 | 0.250 |
Why?
|
| Mycobacteriaceae | 1 | 2007 | 34 | 0.240 |
Why?
|
| Guinea Pigs | 3 | 2020 | 159 | 0.240 |
Why?
|
| Angiomatosis | 1 | 2006 | 5 | 0.240 |
Why?
|
| Immunohistochemistry | 6 | 2011 | 1716 | 0.240 |
Why?
|
| Body Mass Index | 4 | 2022 | 2445 | 0.240 |
Why?
|
| Patient Selection | 1 | 2010 | 738 | 0.240 |
Why?
|
| Adipokines | 2 | 2019 | 57 | 0.240 |
Why?
|
| DNA-Binding Proteins | 4 | 2020 | 1480 | 0.230 |
Why?
|
| Promoter Regions, Genetic | 3 | 2009 | 1246 | 0.230 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2015 | 1419 | 0.230 |
Why?
|
| Diagnostic Errors | 2 | 2020 | 178 | 0.230 |
Why?
|
| Chronic Disease | 3 | 2018 | 1808 | 0.230 |
Why?
|
| Logistic Models | 4 | 2021 | 2134 | 0.230 |
Why?
|
| Immunity, Innate | 3 | 2018 | 835 | 0.230 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 3 | 2021 | 77 | 0.230 |
Why?
|
| Dexamethasone | 1 | 2008 | 365 | 0.230 |
Why?
|
| Phosphoproteins | 2 | 2009 | 337 | 0.220 |
Why?
|
| Aged | 21 | 2025 | 26153 | 0.220 |
Why?
|
| Amino Acid Substitution | 1 | 2006 | 302 | 0.220 |
Why?
|
| Spirometry | 2 | 2024 | 233 | 0.210 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2004 | 61 | 0.210 |
Why?
|
| Cathelicidins | 3 | 2020 | 40 | 0.210 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2023 | 185 | 0.210 |
Why?
|
| Pulmonary Ventilation | 1 | 2004 | 82 | 0.210 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2025 | 155 | 0.210 |
Why?
|
| Methylobacterium | 1 | 2023 | 1 | 0.200 |
Why?
|
| Serine Proteases | 1 | 2024 | 26 | 0.200 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2013 | 848 | 0.200 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 2382 | 0.200 |
Why?
|
| Pneumonia, Bacterial | 2 | 2021 | 113 | 0.200 |
Why?
|
| Bone Marrow Transplantation | 1 | 2004 | 298 | 0.200 |
Why?
|
| Nails | 1 | 2003 | 14 | 0.200 |
Why?
|
| Risk Assessment | 5 | 2021 | 3747 | 0.190 |
Why?
|
| Phylogeny | 4 | 2026 | 917 | 0.190 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2024 | 161 | 0.190 |
Why?
|
| Adult | 26 | 2025 | 40777 | 0.190 |
Why?
|
| Molecular Epidemiology | 1 | 2023 | 73 | 0.190 |
Why?
|
| Th1 Cells | 1 | 2004 | 139 | 0.190 |
Why?
|
| Th2 Cells | 1 | 2004 | 175 | 0.190 |
Why?
|
| Angiopoietins | 1 | 2022 | 12 | 0.190 |
Why?
|
| Thrombin | 1 | 2024 | 172 | 0.190 |
Why?
|
| Soil | 2 | 2022 | 146 | 0.190 |
Why?
|
| Drinking Water | 3 | 2020 | 89 | 0.190 |
Why?
|
| Pancreatic Elastase | 1 | 2022 | 53 | 0.190 |
Why?
|
| Plague | 1 | 2003 | 60 | 0.180 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 2002 | 34 | 0.180 |
Why?
|
| Ossification, Heterotopic | 1 | 2002 | 18 | 0.180 |
Why?
|
| Case-Control Studies | 5 | 2014 | 3623 | 0.180 |
Why?
|
| Antigens, Bacterial | 1 | 2003 | 126 | 0.180 |
Why?
|
| Species Specificity | 2 | 2020 | 546 | 0.180 |
Why?
|
| Lipids | 2 | 2019 | 707 | 0.180 |
Why?
|
| Fibrillins | 2 | 2013 | 9 | 0.180 |
Why?
|
| Graft vs Host Disease | 1 | 2004 | 279 | 0.180 |
Why?
|
| Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2006 | 371 | 0.180 |
Why?
|
| HIV Seropositivity | 1 | 2002 | 119 | 0.180 |
Why?
|
| Glioblastoma | 1 | 2025 | 353 | 0.180 |
Why?
|
| Autophagosomes | 2 | 2021 | 20 | 0.170 |
Why?
|
| Transcription Factor RelA | 2 | 2019 | 86 | 0.170 |
Why?
|
| Tyrosine | 1 | 2002 | 217 | 0.170 |
Why?
|
| Host-Pathogen Interactions | 1 | 2024 | 361 | 0.170 |
Why?
|
| Chest Pain | 2 | 2021 | 99 | 0.170 |
Why?
|
| Prognosis | 6 | 2020 | 4316 | 0.170 |
Why?
|
| Cosmetics | 1 | 2003 | 76 | 0.170 |
Why?
|
| Phagosomes | 2 | 2019 | 40 | 0.170 |
Why?
|
| Leisure Activities | 1 | 2021 | 30 | 0.160 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2002 | 279 | 0.160 |
Why?
|
| Microfilament Proteins | 2 | 2013 | 135 | 0.160 |
Why?
|
| Breast Density | 1 | 2020 | 8 | 0.160 |
Why?
|
| Transfection | 2 | 2015 | 926 | 0.160 |
Why?
|
| Metapneumovirus | 3 | 2007 | 15 | 0.160 |
Why?
|
| Hemoptysis | 1 | 2021 | 35 | 0.160 |
Why?
|
| Bias | 1 | 2021 | 197 | 0.160 |
Why?
|
| MutL Proteins | 1 | 2020 | 3 | 0.160 |
Why?
|
| Motorcycles | 1 | 2020 | 7 | 0.160 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2020 | 12 | 0.160 |
Why?
|
| Virus Internalization | 1 | 2020 | 65 | 0.160 |
Why?
|
| Bronchoalveolar Lavage Fluid | 6 | 2010 | 638 | 0.160 |
Why?
|
| Leukocyte Elastase | 1 | 2020 | 75 | 0.160 |
Why?
|
| Complement C1 Inhibitor Protein | 1 | 2020 | 12 | 0.160 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2015 | 227 | 0.160 |
Why?
|
| Radiation Tolerance | 1 | 2021 | 103 | 0.160 |
Why?
|
| Extracellular Traps | 1 | 2020 | 52 | 0.160 |
Why?
|
| Head Protective Devices | 1 | 2020 | 24 | 0.160 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2021 | 101 | 0.160 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 4 | 2010 | 977 | 0.160 |
Why?
|
| Chromatography, Thin Layer | 1 | 2020 | 24 | 0.160 |
Why?
|
| Calcinosis | 1 | 2002 | 234 | 0.160 |
Why?
|
| DNA Mismatch Repair | 1 | 2020 | 53 | 0.160 |
Why?
|
| Antithrombins | 1 | 2020 | 71 | 0.160 |
Why?
|
| Radiologists | 1 | 2020 | 61 | 0.150 |
Why?
|
| Forkhead Transcription Factors | 2 | 2011 | 207 | 0.150 |
Why?
|
| Databases, Factual | 2 | 2017 | 1490 | 0.150 |
Why?
|
| Radiographic Image Enhancement | 1 | 2020 | 57 | 0.150 |
Why?
|
| Leptin | 3 | 2019 | 248 | 0.150 |
Why?
|
| Protein Subunits | 3 | 2017 | 229 | 0.150 |
Why?
|
| HIV Infections | 4 | 2022 | 3194 | 0.150 |
Why?
|
| Crowding | 1 | 2019 | 37 | 0.150 |
Why?
|
| Propensity Score | 1 | 2021 | 377 | 0.150 |
Why?
|
| RNA, Small Interfering | 3 | 2010 | 637 | 0.150 |
Why?
|
| Observer Variation | 1 | 2020 | 357 | 0.150 |
Why?
|
| Water Microbiology | 2 | 2026 | 85 | 0.150 |
Why?
|
| HEK293 Cells | 1 | 2022 | 741 | 0.150 |
Why?
|
| Adipose Tissue, White | 1 | 2019 | 43 | 0.150 |
Why?
|
| Pulmonary Surfactants | 2 | 2011 | 105 | 0.150 |
Why?
|
| Mitogen-Activated Protein Kinases | 4 | 2012 | 288 | 0.150 |
Why?
|
| Postmenopause | 2 | 2013 | 392 | 0.150 |
Why?
|
| Vitamin A | 1 | 2019 | 60 | 0.150 |
Why?
|
| Mammography | 1 | 2020 | 166 | 0.140 |
Why?
|
| Lymph Nodes | 2 | 2015 | 503 | 0.140 |
Why?
|
| Macrolides | 1 | 2019 | 67 | 0.140 |
Why?
|
| Interleukin-12 | 3 | 2011 | 115 | 0.140 |
Why?
|
| Dyspnea | 1 | 2021 | 250 | 0.140 |
Why?
|
| Biota | 1 | 2018 | 29 | 0.140 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 198 | 0.140 |
Why?
|
| Retrospective Studies | 8 | 2021 | 17291 | 0.140 |
Why?
|
| Shock, Septic | 1 | 2021 | 227 | 0.140 |
Why?
|
| Pulmonary Embolism | 2 | 2014 | 241 | 0.140 |
Why?
|
| Leishmania infantum | 1 | 2018 | 8 | 0.140 |
Why?
|
| Emphysema | 1 | 2019 | 100 | 0.140 |
Why?
|
| Radiation Dosage | 1 | 2020 | 193 | 0.140 |
Why?
|
| Enzyme Activation | 4 | 2017 | 762 | 0.140 |
Why?
|
| Anticoagulants | 1 | 2024 | 748 | 0.140 |
Why?
|
| Osmotic Pressure | 2 | 2017 | 41 | 0.140 |
Why?
|
| Leishmaniasis, Visceral | 1 | 2018 | 24 | 0.140 |
Why?
|
| Protective Factors | 1 | 2018 | 99 | 0.130 |
Why?
|
| Fomites | 1 | 2017 | 6 | 0.130 |
Why?
|
| Antioxidants | 3 | 2008 | 550 | 0.130 |
Why?
|
| Adipocytes | 1 | 2019 | 223 | 0.130 |
Why?
|
| Nicotinic Antagonists | 1 | 2017 | 36 | 0.130 |
Why?
|
| Interleukin-10 | 4 | 2011 | 309 | 0.130 |
Why?
|
| Acute Lung Injury | 1 | 2020 | 305 | 0.130 |
Why?
|
| Computer Simulation | 1 | 2021 | 1003 | 0.130 |
Why?
|
| Interleukin-1beta | 2 | 2009 | 389 | 0.130 |
Why?
|
| Mitral Valve Prolapse | 1 | 2017 | 9 | 0.130 |
Why?
|
| Phenotype | 4 | 2021 | 3155 | 0.130 |
Why?
|
| Wheelchairs | 1 | 2017 | 16 | 0.130 |
Why?
|
| Blotting, Western | 2 | 2010 | 1179 | 0.130 |
Why?
|
| eIF-2 Kinase | 1 | 2017 | 28 | 0.130 |
Why?
|
| Asthma | 4 | 2008 | 1797 | 0.130 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2015 | 919 | 0.130 |
Why?
|
| Mice, Inbred C57BL | 6 | 2021 | 5983 | 0.120 |
Why?
|
| Mice, Transgenic | 3 | 2019 | 2188 | 0.120 |
Why?
|
| Cohort Studies | 6 | 2021 | 6013 | 0.120 |
Why?
|
| Inflammation | 5 | 2019 | 2878 | 0.120 |
Why?
|
| Computers, Handheld | 1 | 2017 | 26 | 0.120 |
Why?
|
| Interferon Regulatory Factor-1 | 2 | 2009 | 17 | 0.120 |
Why?
|
| Contrast Media | 1 | 2020 | 497 | 0.120 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2015 | 1140 | 0.120 |
Why?
|
| Weight Loss | 2 | 2022 | 858 | 0.120 |
Why?
|
| Mice, Inbred BALB C | 3 | 2021 | 1261 | 0.120 |
Why?
|
| Mobility Limitation | 1 | 2017 | 67 | 0.120 |
Why?
|
| Acute Disease | 3 | 2016 | 1036 | 0.120 |
Why?
|
| Serologic Tests | 1 | 2016 | 54 | 0.120 |
Why?
|
| Delayed Diagnosis | 1 | 2017 | 100 | 0.120 |
Why?
|
| Regression Analysis | 3 | 2015 | 1001 | 0.120 |
Why?
|
| Age Factors | 2 | 2021 | 3342 | 0.120 |
Why?
|
| Immunotherapy | 1 | 2021 | 666 | 0.120 |
Why?
|
| Postoperative Care | 1 | 2018 | 286 | 0.120 |
Why?
|
| RNA, Messenger | 4 | 2017 | 2803 | 0.120 |
Why?
|
| Treatment Failure | 2 | 2018 | 360 | 0.120 |
Why?
|
| Protective Agents | 1 | 2016 | 42 | 0.120 |
Why?
|
| Household Articles | 1 | 2016 | 28 | 0.120 |
Why?
|
| Sputum | 3 | 2016 | 302 | 0.120 |
Why?
|
| Head and Neck Neoplasms | 1 | 2021 | 561 | 0.120 |
Why?
|
| Models, Immunological | 1 | 2016 | 99 | 0.120 |
Why?
|
| Testis | 2 | 2009 | 162 | 0.120 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2010 | 2588 | 0.120 |
Why?
|
| Escherichia coli | 1 | 2020 | 835 | 0.110 |
Why?
|
| Hypoxia | 2 | 2021 | 1199 | 0.110 |
Why?
|
| Paramyxoviridae Infections | 2 | 2007 | 12 | 0.110 |
Why?
|
| Hand | 1 | 2017 | 157 | 0.110 |
Why?
|
| Cancer Survivors | 1 | 2021 | 337 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2021 | 881 | 0.110 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily B | 1 | 2015 | 9 | 0.110 |
Why?
|
| Energy-Generating Resources | 1 | 2015 | 6 | 0.110 |
Why?
|
| Antigens, Ly | 1 | 2015 | 45 | 0.110 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 485 | 0.110 |
Why?
|
| Internationality | 1 | 2016 | 156 | 0.110 |
Why?
|
| Louisiana | 1 | 2015 | 31 | 0.110 |
Why?
|
| Cystic Fibrosis | 2 | 2002 | 1161 | 0.110 |
Why?
|
| RNA Splice Sites | 1 | 2015 | 51 | 0.110 |
Why?
|
| Adolescent | 10 | 2025 | 22530 | 0.110 |
Why?
|
| Leg | 1 | 2017 | 242 | 0.110 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2017 | 231 | 0.110 |
Why?
|
| Pulmonary Surfactant-Associated Protein C | 1 | 2015 | 45 | 0.110 |
Why?
|
| Bacterial Load | 1 | 2015 | 67 | 0.110 |
Why?
|
| Receptors, Nicotinic | 1 | 2017 | 327 | 0.110 |
Why?
|
| Biomass | 1 | 2015 | 96 | 0.110 |
Why?
|
| Aged, 80 and over | 7 | 2021 | 8333 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 3 | 2008 | 307 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2020 | 769 | 0.110 |
Why?
|
| Systole | 1 | 2015 | 181 | 0.110 |
Why?
|
| Colony Count, Microbial | 1 | 2014 | 89 | 0.110 |
Why?
|
| Hypertension, Pulmonary | 1 | 2006 | 1957 | 0.110 |
Why?
|
| Referral and Consultation | 1 | 2021 | 867 | 0.100 |
Why?
|
| Transgenes | 1 | 2015 | 190 | 0.100 |
Why?
|
| Calcifediol | 1 | 2014 | 31 | 0.100 |
Why?
|
| Phosphorylation | 3 | 2017 | 1707 | 0.100 |
Why?
|
| Cytoplasm | 1 | 2015 | 254 | 0.100 |
Why?
|
| International Cooperation | 1 | 2015 | 197 | 0.100 |
Why?
|
| Liver | 3 | 2020 | 1896 | 0.100 |
Why?
|
| Pneumonectomy | 1 | 2016 | 167 | 0.100 |
Why?
|
| Tobacco Products | 1 | 2015 | 84 | 0.100 |
Why?
|
| Postoperative Complications | 2 | 2018 | 2970 | 0.100 |
Why?
|
| Data Collection | 1 | 2017 | 640 | 0.100 |
Why?
|
| Calcitriol | 1 | 2014 | 57 | 0.100 |
Why?
|
| Hepatorenal Syndrome | 1 | 2013 | 15 | 0.100 |
Why?
|
| Drug Therapy, Combination | 3 | 2019 | 1044 | 0.100 |
Why?
|
| DNA | 1 | 2020 | 1435 | 0.100 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2013 | 95 | 0.100 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2013 | 36 | 0.100 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 89 | 0.100 |
Why?
|
| Pulmonary Edema | 2 | 2004 | 105 | 0.100 |
Why?
|
| Surface Properties | 1 | 2014 | 386 | 0.100 |
Why?
|
| Acanthamoeba | 1 | 2013 | 5 | 0.100 |
Why?
|
| Hemoglobins, Abnormal | 1 | 2013 | 8 | 0.100 |
Why?
|
| Partial Pressure | 1 | 2013 | 30 | 0.100 |
Why?
|
| Fetal Hemoglobin | 1 | 2013 | 8 | 0.100 |
Why?
|
| Marfan Syndrome | 1 | 2013 | 46 | 0.100 |
Why?
|
| Oxyhemoglobins | 1 | 2013 | 28 | 0.100 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 3 | 2010 | 264 | 0.100 |
Why?
|
| Pleural Effusion | 1 | 2013 | 59 | 0.100 |
Why?
|
| Biodiversity | 1 | 2016 | 311 | 0.100 |
Why?
|
| Thymectomy | 1 | 2012 | 15 | 0.090 |
Why?
|
| Intracellular Space | 1 | 2013 | 64 | 0.090 |
Why?
|
| Caspase Inhibitors | 1 | 2013 | 81 | 0.090 |
Why?
|
| Critical Illness | 1 | 2019 | 900 | 0.090 |
Why?
|
| Colorado | 2 | 2021 | 4554 | 0.090 |
Why?
|
| Cell Movement | 1 | 2017 | 959 | 0.090 |
Why?
|
| Thymoma | 1 | 2012 | 37 | 0.090 |
Why?
|
| Neutrophil Activation | 1 | 2013 | 84 | 0.090 |
Why?
|
| Disease Management | 1 | 2017 | 653 | 0.090 |
Why?
|
| Sulfones | 1 | 2013 | 127 | 0.090 |
Why?
|
| Water Supply | 1 | 2013 | 89 | 0.090 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2012 | 68 | 0.090 |
Why?
|
| Adenoviridae | 1 | 2013 | 199 | 0.090 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2012 | 18 | 0.090 |
Why?
|
| Adaptation, Physiological | 1 | 2016 | 560 | 0.090 |
Why?
|
| Caspase 3 | 1 | 2013 | 242 | 0.090 |
Why?
|
| Quality of Life | 2 | 2021 | 3204 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2014 | 688 | 0.090 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 1 | 2021 | 1189 | 0.090 |
Why?
|
| Exercise | 2 | 2021 | 2198 | 0.090 |
Why?
|
| Length of Stay | 1 | 2018 | 1349 | 0.090 |
Why?
|
| Hyperglycemia | 1 | 2016 | 379 | 0.090 |
Why?
|
| Pandemics | 1 | 2020 | 1707 | 0.090 |
Why?
|
| Nitriles | 1 | 2013 | 207 | 0.090 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2012 | 133 | 0.090 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2018 | 610 | 0.090 |
Why?
|
| Microbial Sensitivity Tests | 3 | 2015 | 364 | 0.090 |
Why?
|
| Whole-Body Irradiation | 1 | 2012 | 74 | 0.090 |
Why?
|
| Down-Regulation | 2 | 2010 | 618 | 0.090 |
Why?
|
| Lipid Metabolism | 1 | 2015 | 529 | 0.090 |
Why?
|
| Amino Acid Sequence | 2 | 2013 | 2129 | 0.090 |
Why?
|
| Casein Kinase II | 2 | 2009 | 22 | 0.090 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2011 | 18 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2013 | 260 | 0.080 |
Why?
|
| Drug Discovery | 1 | 2012 | 153 | 0.080 |
Why?
|
| Splenectomy | 1 | 2011 | 61 | 0.080 |
Why?
|
| Phosphatidylglycerols | 1 | 2011 | 18 | 0.080 |
Why?
|
| Forkhead Box Protein O3 | 1 | 2010 | 18 | 0.080 |
Why?
|
| Cell Growth Processes | 1 | 2010 | 48 | 0.080 |
Why?
|
| Blotting, Northern | 1 | 2010 | 203 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2010 | 64 | 0.080 |
Why?
|
| Pelvis | 1 | 2012 | 125 | 0.080 |
Why?
|
| Pulmonary Surfactant-Associated Protein D | 1 | 2010 | 31 | 0.080 |
Why?
|
| Emergency Service, Hospital | 2 | 2021 | 2381 | 0.080 |
Why?
|
| Cerebrospinal Fluid Otorrhea | 1 | 2010 | 6 | 0.080 |
Why?
|
| Oxidative Stress | 2 | 2010 | 1356 | 0.080 |
Why?
|
| Earache | 1 | 2010 | 6 | 0.080 |
Why?
|
| Facial Nerve Diseases | 1 | 2010 | 8 | 0.080 |
Why?
|
| Liver Failure | 1 | 2011 | 83 | 0.080 |
Why?
|
| Computer Communication Networks | 1 | 2010 | 32 | 0.080 |
Why?
|
| G1 Phase | 1 | 2010 | 65 | 0.080 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2014 | 372 | 0.080 |
Why?
|
| S Phase | 1 | 2010 | 78 | 0.080 |
Why?
|
| Eicosanoids | 1 | 2011 | 58 | 0.080 |
Why?
|
| Mastoiditis | 1 | 2010 | 10 | 0.080 |
Why?
|
| Bacterial Proteins | 3 | 2016 | 967 | 0.080 |
Why?
|
| Anti-HIV Agents | 2 | 2018 | 912 | 0.080 |
Why?
|
| Time Factors | 4 | 2021 | 7123 | 0.080 |
Why?
|
| Sinus Thrombosis, Intracranial | 1 | 2010 | 25 | 0.080 |
Why?
|
| Temporal Bone | 1 | 2010 | 48 | 0.080 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2010 | 119 | 0.080 |
Why?
|
| Bacteria | 1 | 2016 | 765 | 0.080 |
Why?
|
| In Vitro Techniques | 2 | 2020 | 1048 | 0.080 |
Why?
|
| Purpura | 1 | 2009 | 18 | 0.080 |
Why?
|
| Linezolid | 2 | 2020 | 25 | 0.080 |
Why?
|
| Delivery of Health Care | 1 | 2017 | 946 | 0.080 |
Why?
|
| Smoking Prevention | 1 | 2010 | 166 | 0.080 |
Why?
|
| STAT6 Transcription Factor | 1 | 2009 | 24 | 0.070 |
Why?
|
| Lymphocyte Antigen 96 | 1 | 2009 | 23 | 0.070 |
Why?
|
| United States | 6 | 2022 | 16098 | 0.070 |
Why?
|
| Arginase | 1 | 2009 | 26 | 0.070 |
Why?
|
| Disaster Planning | 1 | 2010 | 103 | 0.070 |
Why?
|
| Transcription, Genetic | 3 | 2016 | 1454 | 0.070 |
Why?
|
| Child, Preschool | 6 | 2025 | 11853 | 0.070 |
Why?
|
| Occupational Health | 1 | 2012 | 211 | 0.070 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2009 | 88 | 0.070 |
Why?
|
| Transcriptional Activation | 1 | 2010 | 372 | 0.070 |
Why?
|
| Hypoglycemia | 1 | 2013 | 479 | 0.070 |
Why?
|
| Cell Line, Tumor | 2 | 2021 | 3542 | 0.070 |
Why?
|
| Metalloporphyrins | 1 | 2008 | 63 | 0.070 |
Why?
|
| Spleen | 2 | 2008 | 508 | 0.070 |
Why?
|
| Genes, Bacterial | 1 | 2008 | 152 | 0.070 |
Why?
|
| Tuberculosis, Meningeal | 1 | 2008 | 7 | 0.070 |
Why?
|
| Gentian Violet | 1 | 2008 | 4 | 0.070 |
Why?
|
| Severity of Illness Index | 3 | 2019 | 2930 | 0.070 |
Why?
|
| Phenazines | 1 | 2008 | 17 | 0.070 |
Why?
|
| Pneumonia | 2 | 2012 | 636 | 0.070 |
Why?
|
| Testicular Neoplasms | 1 | 2009 | 111 | 0.070 |
Why?
|
| Communicable Disease Control | 1 | 2008 | 85 | 0.070 |
Why?
|
| Adipose Tissue | 1 | 2012 | 645 | 0.070 |
Why?
|
| Blood Pressure | 1 | 2015 | 1779 | 0.070 |
Why?
|
| Occupational Exposure | 1 | 2012 | 355 | 0.070 |
Why?
|
| HIV-1 | 1 | 2014 | 908 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 776 | 0.070 |
Why?
|
| Incidence | 1 | 2015 | 2923 | 0.070 |
Why?
|
| Arginine | 1 | 2009 | 264 | 0.070 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2009 | 253 | 0.070 |
Why?
|
| Registries | 1 | 2017 | 2406 | 0.070 |
Why?
|
| Hepatitis C, Chronic | 1 | 2009 | 153 | 0.070 |
Why?
|
| Oxygen | 1 | 2013 | 978 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2011 | 309 | 0.070 |
Why?
|
| Staining and Labeling | 1 | 2008 | 153 | 0.070 |
Why?
|
| Social Media | 1 | 2010 | 166 | 0.070 |
Why?
|
| Chemotaxis | 1 | 2008 | 122 | 0.070 |
Why?
|
| Cell Nucleus | 1 | 2010 | 588 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2008 | 174 | 0.060 |
Why?
|
| Mutation | 2 | 2017 | 4075 | 0.060 |
Why?
|
| Toll-Like Receptor 2 | 1 | 2008 | 125 | 0.060 |
Why?
|
| Telemedicine | 1 | 2017 | 961 | 0.060 |
Why?
|
| Global Health | 1 | 2010 | 403 | 0.060 |
Why?
|
| Health Status | 2 | 2021 | 832 | 0.060 |
Why?
|
| Anemia, Sickle Cell | 1 | 2011 | 318 | 0.060 |
Why?
|
| Estrogens | 1 | 2010 | 367 | 0.060 |
Why?
|
| Prospective Studies | 3 | 2016 | 8057 | 0.060 |
Why?
|
| Hydrogen-Ion Concentration | 2 | 2020 | 531 | 0.060 |
Why?
|
| Child | 7 | 2025 | 22707 | 0.060 |
Why?
|
| Tumor Burden | 2 | 2021 | 325 | 0.060 |
Why?
|
| Pacific Islands | 1 | 2026 | 5 | 0.060 |
Why?
|
| Laparoscopy | 1 | 2011 | 481 | 0.060 |
Why?
|
| Fibroma | 1 | 2006 | 21 | 0.060 |
Why?
|
| Cross-Sectional Studies | 4 | 2021 | 5905 | 0.060 |
Why?
|
| Tricuspid Valve | 1 | 2006 | 43 | 0.060 |
Why?
|
| Cell Transformation, Viral | 1 | 2006 | 23 | 0.060 |
Why?
|
| Biomarkers | 4 | 2021 | 4295 | 0.060 |
Why?
|
| Heart Neoplasms | 1 | 2006 | 56 | 0.060 |
Why?
|
| Autoantibodies | 1 | 2013 | 1509 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2006 | 138 | 0.060 |
Why?
|
| Caspase 1 | 1 | 2006 | 145 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2008 | 969 | 0.060 |
Why?
|
| Granuloma, Respiratory Tract | 1 | 2005 | 13 | 0.060 |
Why?
|
| Phenylalanine | 1 | 2006 | 69 | 0.060 |
Why?
|
| Obesity | 1 | 2019 | 3116 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 418 | 0.060 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2010 | 641 | 0.060 |
Why?
|
| Internet | 1 | 2010 | 689 | 0.060 |
Why?
|
| Combined Modality Therapy | 2 | 2021 | 1266 | 0.060 |
Why?
|
| Lysosomes | 2 | 2021 | 131 | 0.060 |
Why?
|
| Nutritional Status | 2 | 2018 | 353 | 0.060 |
Why?
|
| Kartagener Syndrome | 1 | 2005 | 31 | 0.060 |
Why?
|
| Fatal Outcome | 1 | 2006 | 305 | 0.060 |
Why?
|
| Radiography | 2 | 2004 | 852 | 0.060 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2002 | 153 | 0.060 |
Why?
|
| Antibiotics, Antitubercular | 1 | 2025 | 35 | 0.050 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2008 | 395 | 0.050 |
Why?
|
| Tracheal Diseases | 1 | 2004 | 15 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2025 | 3413 | 0.050 |
Why?
|
| Fatty Acids | 1 | 2008 | 457 | 0.050 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2007 | 507 | 0.050 |
Why?
|
| Tryptophan | 1 | 2006 | 182 | 0.050 |
Why?
|
| Esophageal Diseases | 1 | 2004 | 30 | 0.050 |
Why?
|
| Lymphocytes | 2 | 2006 | 376 | 0.050 |
Why?
|
| Sex Characteristics | 1 | 2010 | 782 | 0.050 |
Why?
|
| Perfusion | 1 | 2025 | 251 | 0.050 |
Why?
|
| Neovascularization, Pathologic | 1 | 2005 | 286 | 0.050 |
Why?
|
| Sequence Analysis, DNA | 1 | 2007 | 777 | 0.050 |
Why?
|
| Confidence Intervals | 2 | 2021 | 330 | 0.050 |
Why?
|
| Body Weight | 2 | 2019 | 971 | 0.050 |
Why?
|
| Chemokines, CXC | 1 | 2004 | 68 | 0.050 |
Why?
|
| Signal Transduction | 2 | 2010 | 5216 | 0.050 |
Why?
|
| Anthrax | 1 | 2003 | 9 | 0.050 |
Why?
|
| Severe Acute Respiratory Syndrome | 1 | 2003 | 19 | 0.050 |
Why?
|
| Abnormalities, Multiple | 1 | 2005 | 199 | 0.050 |
Why?
|
| Survival Rate | 1 | 2008 | 2090 | 0.050 |
Why?
|
| Callitrichinae | 1 | 2023 | 1 | 0.050 |
Why?
|
| 5' Flanking Region | 1 | 2003 | 9 | 0.050 |
Why?
|
| Callithrix | 1 | 2023 | 10 | 0.050 |
Why?
|
| Communicable Diseases, Emerging | 1 | 2003 | 39 | 0.050 |
Why?
|
| NF-KappaB Inhibitor alpha | 1 | 2003 | 50 | 0.050 |
Why?
|
| Cell Proliferation | 1 | 2010 | 2507 | 0.050 |
Why?
|
| Color | 1 | 2003 | 81 | 0.050 |
Why?
|
| Data Accuracy | 1 | 2023 | 65 | 0.050 |
Why?
|
| Yersinia pestis | 1 | 2003 | 45 | 0.050 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2010 | 919 | 0.050 |
Why?
|
| Coronavirus | 1 | 2003 | 47 | 0.050 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2003 | 88 | 0.050 |
Why?
|
| I-kappa B Proteins | 1 | 2003 | 75 | 0.050 |
Why?
|
| Respiratory Function Tests | 1 | 2004 | 544 | 0.050 |
Why?
|
| Nuclear Proteins | 2 | 2009 | 740 | 0.050 |
Why?
|
| Infant | 4 | 2025 | 10077 | 0.050 |
Why?
|
| Gastroesophageal Reflux | 2 | 2020 | 237 | 0.050 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2012 | 1371 | 0.050 |
Why?
|
| Nitric Oxide Synthase Type I | 1 | 2002 | 30 | 0.050 |
Why?
|
| Airway Obstruction | 1 | 2004 | 153 | 0.050 |
Why?
|
| Chromosome Mapping | 1 | 2023 | 506 | 0.050 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2003 | 194 | 0.040 |
Why?
|
| Review Literature as Topic | 1 | 2002 | 52 | 0.040 |
Why?
|
| Treatment Refusal | 1 | 2002 | 98 | 0.040 |
Why?
|
| Cell Differentiation | 1 | 2010 | 2046 | 0.040 |
Why?
|
| Oxides | 1 | 2022 | 47 | 0.040 |
Why?
|
| Vascular Diseases | 1 | 2004 | 252 | 0.040 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2002 | 130 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2002 | 203 | 0.040 |
Why?
|
| Epithelium | 1 | 2002 | 310 | 0.040 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2021 | 23 | 0.040 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 3 | 2011 | 126 | 0.040 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2021 | 43 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2025 | 779 | 0.040 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2021 | 82 | 0.040 |
Why?
|
| Behavioral Risk Factor Surveillance System | 1 | 2021 | 57 | 0.040 |
Why?
|
| Autophagy-Related Proteins | 1 | 2021 | 46 | 0.040 |
Why?
|
| Lymphocyte Depletion | 1 | 2021 | 132 | 0.040 |
Why?
|
| Sulfuric Acids | 1 | 2020 | 8 | 0.040 |
Why?
|
| Vietnam | 1 | 2020 | 27 | 0.040 |
Why?
|
| Reactive Oxygen Species | 1 | 2003 | 611 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2004 | 1374 | 0.040 |
Why?
|
| Superoxides | 2 | 2013 | 198 | 0.040 |
Why?
|
| Biological Assay | 1 | 2021 | 130 | 0.040 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2003 | 456 | 0.040 |
Why?
|
| Developing Countries | 1 | 2002 | 316 | 0.040 |
Why?
|
| Respiratory Aspiration | 1 | 2020 | 32 | 0.040 |
Why?
|
| Multivariate Analysis | 1 | 2004 | 1547 | 0.040 |
Why?
|
| Disease Outbreaks | 1 | 2003 | 419 | 0.040 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 1127 | 0.040 |
Why?
|
| Recurrence | 2 | 2018 | 1138 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2008 | 1734 | 0.040 |
Why?
|
| Primary Cell Culture | 1 | 2020 | 172 | 0.040 |
Why?
|
| Injections, Intravenous | 1 | 2020 | 197 | 0.040 |
Why?
|
| Early Diagnosis | 1 | 2021 | 251 | 0.040 |
Why?
|
| China | 1 | 2020 | 270 | 0.040 |
Why?
|
| 3-Hydroxysteroid Dehydrogenases | 1 | 2019 | 8 | 0.040 |
Why?
|
| Australia | 1 | 2020 | 288 | 0.040 |
Why?
|
| Iron | 1 | 2022 | 357 | 0.040 |
Why?
|
| Retinal Dehydrogenase | 1 | 2019 | 29 | 0.040 |
Why?
|
| Bacillus | 1 | 2019 | 17 | 0.040 |
Why?
|
| Culture Media, Conditioned | 1 | 2019 | 112 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2020 | 204 | 0.040 |
Why?
|
| Insurance Claim Review | 1 | 2019 | 83 | 0.040 |
Why?
|
| Multiprotein Complexes | 1 | 2020 | 172 | 0.040 |
Why?
|
| Topography, Medical | 1 | 2018 | 10 | 0.040 |
Why?
|
| Kanamycin | 1 | 2018 | 10 | 0.040 |
Why?
|
| Capreomycin | 1 | 2018 | 3 | 0.040 |
Why?
|
| Protein Folding | 1 | 2020 | 276 | 0.040 |
Why?
|
| Cell Wall | 1 | 2019 | 57 | 0.040 |
Why?
|
| Diarylquinolines | 1 | 2018 | 16 | 0.040 |
Why?
|
| Levofloxacin | 1 | 2018 | 21 | 0.040 |
Why?
|
| Carbapenems | 1 | 2018 | 27 | 0.040 |
Why?
|
| Clofazimine | 1 | 2018 | 15 | 0.040 |
Why?
|
| Biomarkers, Tumor | 1 | 2005 | 1321 | 0.030 |
Why?
|
| Child Nutrition Disorders | 1 | 2018 | 20 | 0.030 |
Why?
|
| Hyperinsulinism | 1 | 2019 | 114 | 0.030 |
Why?
|
| ROC Curve | 1 | 2020 | 617 | 0.030 |
Why?
|
| Nucleosomes | 1 | 2020 | 163 | 0.030 |
Why?
|
| Health Services | 1 | 2019 | 113 | 0.030 |
Why?
|
| Intensive Care Units | 2 | 2021 | 924 | 0.030 |
Why?
|
| B-Lymphocytes | 1 | 2004 | 870 | 0.030 |
Why?
|
| Water-Electrolyte Balance | 1 | 2018 | 37 | 0.030 |
Why?
|
| Interleukin-1 | 1 | 2002 | 961 | 0.030 |
Why?
|
| Craniocerebral Trauma | 1 | 2020 | 178 | 0.030 |
Why?
|
| Early Ambulation | 1 | 2018 | 25 | 0.030 |
Why?
|
| Health Resources | 1 | 2019 | 130 | 0.030 |
Why?
|
| Child Nutritional Physiological Phenomena | 1 | 2018 | 106 | 0.030 |
Why?
|
| Repressor Proteins | 1 | 2021 | 429 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 3904 | 0.030 |
Why?
|
| Adenosine Triphosphate | 1 | 2020 | 500 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 1327 | 0.030 |
Why?
|
| Europe | 1 | 2018 | 418 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2019 | 194 | 0.030 |
Why?
|
| Nitrosation | 1 | 2017 | 8 | 0.030 |
Why?
|
| Malnutrition | 1 | 2018 | 86 | 0.030 |
Why?
|
| Enterocytes | 1 | 2017 | 16 | 0.030 |
Why?
|
| Immunity, Cellular | 1 | 2019 | 274 | 0.030 |
Why?
|
| Middle East | 1 | 2017 | 18 | 0.030 |
Why?
|
| Family Characteristics | 1 | 2018 | 195 | 0.030 |
Why?
|
| Nucleic Acid Conformation | 1 | 2020 | 723 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2021 | 1471 | 0.030 |
Why?
|
| Alcohol Drinking | 1 | 2004 | 837 | 0.030 |
Why?
|
| Proteomics | 1 | 2004 | 1188 | 0.030 |
Why?
|
| RNA, Double-Stranded | 1 | 2017 | 51 | 0.030 |
Why?
|
| Gambia | 1 | 2016 | 8 | 0.030 |
Why?
|
| Sepsis | 1 | 2003 | 664 | 0.030 |
Why?
|
| Coinfection | 1 | 2018 | 143 | 0.030 |
Why?
|
| Two-Hybrid System Techniques | 2 | 2009 | 59 | 0.030 |
Why?
|
| Tumor Microenvironment | 1 | 2021 | 734 | 0.030 |
Why?
|
| Age of Onset | 1 | 2018 | 555 | 0.030 |
Why?
|
| Regulon | 1 | 2016 | 34 | 0.030 |
Why?
|
| Uganda | 1 | 2016 | 89 | 0.030 |
Why?
|
| Models, Animal | 1 | 2018 | 393 | 0.030 |
Why?
|
| Nitrogen Oxides | 1 | 2016 | 46 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2021 | 1323 | 0.030 |
Why?
|
| Self Report | 1 | 2021 | 870 | 0.030 |
Why?
|
| Baths | 1 | 2016 | 14 | 0.030 |
Why?
|
| Family Health | 1 | 2017 | 191 | 0.030 |
Why?
|
| Syndrome | 1 | 2017 | 381 | 0.030 |
Why?
|
| Humidity | 1 | 2016 | 49 | 0.030 |
Why?
|
| Program Development | 1 | 2018 | 368 | 0.030 |
Why?
|
| Housing | 1 | 2016 | 142 | 0.030 |
Why?
|
| Pedigree | 1 | 2017 | 515 | 0.030 |
Why?
|
| Metabolic Syndrome | 1 | 2019 | 360 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 318 | 0.030 |
Why?
|
| Mutation, Missense | 1 | 2017 | 335 | 0.030 |
Why?
|
| Science | 1 | 2016 | 55 | 0.030 |
Why?
|
| Mental Disorders | 1 | 2004 | 1163 | 0.030 |
Why?
|
| Ethiodized Oil | 1 | 2014 | 10 | 0.030 |
Why?
|
| Guideline Adherence | 1 | 2019 | 586 | 0.030 |
Why?
|
| Blood Transfusion | 1 | 2018 | 409 | 0.030 |
Why?
|
| Hepatic Artery | 1 | 2014 | 53 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2016 | 312 | 0.030 |
Why?
|
| Dyneins | 2 | 2005 | 34 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2019 | 838 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2018 | 740 | 0.030 |
Why?
|
| Mental Health | 1 | 2021 | 793 | 0.030 |
Why?
|
| Smoking Cessation | 1 | 2018 | 440 | 0.030 |
Why?
|
| Colitis | 1 | 2017 | 280 | 0.030 |
Why?
|
| Mice, Knockout | 1 | 2021 | 3124 | 0.020 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2014 | 93 | 0.020 |
Why?
|
| Recovery of Function | 1 | 2018 | 716 | 0.020 |
Why?
|
| Patient Satisfaction | 1 | 2018 | 709 | 0.020 |
Why?
|
| Hartmannella | 1 | 2013 | 2 | 0.020 |
Why?
|
| Sex Factors | 1 | 2019 | 2105 | 0.020 |
Why?
|
| Rituximab | 1 | 2013 | 210 | 0.020 |
Why?
|
| Water | 1 | 2016 | 445 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2013 | 247 | 0.020 |
Why?
|
| Clinical Competence | 1 | 2020 | 1243 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2014 | 401 | 0.020 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2012 | 140 | 0.020 |
Why?
|
| Laparoscopes | 1 | 2011 | 7 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2014 | 1082 | 0.020 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2011 | 55 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 1581 | 0.020 |
Why?
|
| Lipopeptides | 1 | 2011 | 17 | 0.020 |
Why?
|
| Antibodies, Viral | 2 | 2007 | 674 | 0.020 |
Why?
|
| Cholecystectomy, Laparoscopic | 1 | 2011 | 55 | 0.020 |
Why?
|
| Plasma Cells | 1 | 2011 | 79 | 0.020 |
Why?
|
| Surveys and Questionnaires | 2 | 2019 | 6066 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 1891 | 0.020 |
Why?
|
| Group IV Phospholipases A2 | 1 | 2011 | 46 | 0.020 |
Why?
|
| Taiwan | 1 | 2010 | 48 | 0.020 |
Why?
|
| Organizational Case Studies | 1 | 2010 | 69 | 0.020 |
Why?
|
| Glutathione Peroxidase | 1 | 2010 | 41 | 0.020 |
Why?
|
| Free Radical Scavengers | 1 | 2010 | 82 | 0.020 |
Why?
|
| Catalase | 1 | 2010 | 134 | 0.020 |
Why?
|
| Cyclooxygenase 2 | 1 | 2011 | 166 | 0.020 |
Why?
|
| Students | 1 | 2016 | 651 | 0.020 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2010 | 196 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2002 | 440 | 0.020 |
Why?
|
| Acetylcysteine | 1 | 2010 | 139 | 0.020 |
Why?
|
| Toll-Like Receptors | 1 | 2011 | 193 | 0.020 |
Why?
|
| Lipoproteins | 1 | 2011 | 166 | 0.020 |
Why?
|
| U937 Cells | 1 | 2009 | 28 | 0.020 |
Why?
|
| Equipment Design | 1 | 2011 | 525 | 0.020 |
Why?
|
| Cysteine | 1 | 2011 | 211 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2010 | 267 | 0.020 |
Why?
|
| Spermatids | 1 | 2009 | 25 | 0.020 |
Why?
|
| Biomedical Research | 1 | 2016 | 717 | 0.020 |
Why?
|
| Blood Cells | 1 | 2009 | 38 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2012 | 1300 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2003 | 2883 | 0.020 |
Why?
|
| Environment | 1 | 2010 | 293 | 0.020 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2002 | 624 | 0.020 |
Why?
|
| Ecosystem | 1 | 2013 | 478 | 0.020 |
Why?
|
| Enzyme Inhibitors | 2 | 2002 | 820 | 0.020 |
Why?
|
| Staphylococcus epidermidis | 1 | 2009 | 79 | 0.020 |
Why?
|
| Superoxide Dismutase | 1 | 2010 | 308 | 0.020 |
Why?
|
| Hospitals | 1 | 2013 | 732 | 0.020 |
Why?
|
| Fimbriae, Bacterial | 1 | 2008 | 36 | 0.020 |
Why?
|
| Biopsy | 1 | 2011 | 1082 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2011 | 1162 | 0.020 |
Why?
|
| Saskatchewan | 1 | 2007 | 8 | 0.020 |
Why?
|
| X-Rays | 1 | 2007 | 27 | 0.020 |
Why?
|
| Nucleocapsid Proteins | 1 | 2007 | 28 | 0.020 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2009 | 276 | 0.020 |
Why?
|
| Diabetes Mellitus | 1 | 2016 | 1097 | 0.020 |
Why?
|
| Phagocytosis | 1 | 2008 | 296 | 0.020 |
Why?
|
| DNA, Ribosomal | 1 | 2007 | 84 | 0.020 |
Why?
|
| Molecular Structure | 1 | 2008 | 486 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2010 | 1067 | 0.020 |
Why?
|
| Seroepidemiologic Studies | 1 | 2007 | 171 | 0.020 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2010 | 2028 | 0.010 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2008 | 749 | 0.010 |
Why?
|
| Gene Expression Profiling | 1 | 2013 | 1767 | 0.010 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2006 | 132 | 0.010 |
Why?
|
| Axonemal Dyneins | 1 | 2005 | 8 | 0.010 |
Why?
|
| Mice, Obese | 1 | 2005 | 68 | 0.010 |
Why?
|
| Gene Expression Regulation, Bacterial | 1 | 2008 | 337 | 0.010 |
Why?
|
| DNA, Bacterial | 1 | 2007 | 320 | 0.010 |
Why?
|
| Blood Glucose | 1 | 2016 | 2341 | 0.010 |
Why?
|
| HSP40 Heat-Shock Proteins | 1 | 2005 | 25 | 0.010 |
Why?
|
| Protein Isoforms | 1 | 2006 | 397 | 0.010 |
Why?
|
| Genetic Linkage | 1 | 2005 | 272 | 0.010 |
Why?
|
| Heat-Shock Proteins | 1 | 2005 | 139 | 0.010 |
Why?
|
| Nasal Mucosa | 1 | 2005 | 112 | 0.010 |
Why?
|
| Health Services Administration | 1 | 2004 | 9 | 0.010 |
Why?
|
| Extravascular Lung Water | 1 | 2004 | 9 | 0.010 |
Why?
|
| Nitrites | 1 | 2004 | 87 | 0.010 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2004 | 110 | 0.010 |
Why?
|
| Hong Kong | 1 | 2003 | 7 | 0.010 |
Why?
|
| t-Complex Genome Region | 1 | 2003 | 3 | 0.010 |
Why?
|
| Viral Fusion Proteins | 1 | 2003 | 21 | 0.010 |
Why?
|
| Testicular Hormones | 1 | 2003 | 8 | 0.010 |
Why?
|
| Colorectal Neoplasms | 1 | 2012 | 866 | 0.010 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2009 | 2524 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2007 | 1368 | 0.010 |
Why?
|
| Demography | 1 | 2004 | 282 | 0.010 |
Why?
|
| Uric Acid | 1 | 2004 | 167 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2014 | 2214 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2003 | 318 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 2003 | 186 | 0.010 |
Why?
|
| Deglutition Disorders | 1 | 2004 | 154 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 2003 | 335 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2003 | 362 | 0.010 |
Why?
|
| Probability | 1 | 2003 | 307 | 0.010 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2002 | 23 | 0.010 |
Why?
|
| Ascorbic Acid | 1 | 2004 | 184 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2003 | 428 | 0.010 |
Why?
|
| Chromones | 1 | 2002 | 43 | 0.010 |
Why?
|
| Glutathione | 1 | 2004 | 370 | 0.010 |
Why?
|
| Canada | 1 | 2003 | 431 | 0.010 |
Why?
|
| Growth Inhibitors | 1 | 2002 | 39 | 0.010 |
Why?
|
| Mice, Inbred C3H | 1 | 2002 | 254 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2002 | 88 | 0.010 |
Why?
|
| Blood Proteins | 1 | 2004 | 239 | 0.010 |
Why?
|
| Flavonoids | 1 | 2002 | 85 | 0.010 |
Why?
|
| Indomethacin | 1 | 2002 | 76 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 798 | 0.010 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 82 | 0.010 |
Why?
|
| MAP Kinase Kinase 1 | 1 | 2002 | 70 | 0.010 |
Why?
|
| Ubiquitin-Protein Ligases | 1 | 2003 | 192 | 0.010 |
Why?
|
| Morpholines | 1 | 2002 | 130 | 0.010 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2002 | 171 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2002 | 180 | 0.010 |
Why?
|
| Ultrasonography | 1 | 2005 | 785 | 0.010 |
Why?
|
| Injury Severity Score | 1 | 2003 | 599 | 0.010 |
Why?
|
| Rats | 1 | 2009 | 5584 | 0.010 |
Why?
|
| Imidazoles | 1 | 2002 | 247 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 2002 | 321 | 0.010 |
Why?
|
| Cell Division | 1 | 2002 | 756 | 0.010 |
Why?
|
| Base Sequence | 1 | 2003 | 2170 | 0.010 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2004 | 778 | 0.010 |
Why?
|
| Cell Survival | 1 | 2002 | 1100 | 0.010 |
Why?
|
| Proteome | 1 | 2004 | 514 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2003 | 1997 | 0.010 |
Why?
|
| Proteins | 1 | 2004 | 1023 | 0.010 |
Why?
|
| Interleukin-6 | 1 | 2002 | 776 | 0.010 |
Why?
|
| Pyridines | 1 | 2002 | 609 | 0.010 |
Why?
|
| Young Adult | 1 | 2010 | 14219 | 0.010 |
Why?
|
| Veterans | 1 | 2004 | 1635 | 0.010 |
Why?
|